Literature DB >> 3401250

Correlation between the cytotoxicity of melphalan and DNA crosslinks as detected by the ethidium bromide fluorescence assay in the F1 variant of B16 melanoma cells.

S T Garcia1, A McQuillan, L Panasci.   

Abstract

The relationship between DNA crosslinks and cell death as a result of exposure to melphalan (MLN) was studied in the F1 variant of B16 melanoma cells. The formation of DNA crosslinks is believed to represent the lethal lesion following exposure of cells to bifunctional alkylating agents. The production of DNA crosslinks by MLN was determined by the recently described ethidium bromide fluorescence assay [De Jong et al., Int. J. Cancer 37, 557 (1986)]. A direct correlation between the percentage of DNA crosslinks (Ct) and cytotoxicity of melphalan has not been previously reported utilizing the fluorescence assay. The cytotoxicity of MLN and the production of DNA crosslinks by this drug were determined following a 1-hr incubation at 37 degrees. The concentrations of MLN necessary to reduce colony growth to 37% of control and 10% of control were 6.7 microM (EC37) and 26 microM (EC10) respectively. Utilizing the ethidium bromide fluorescence assay (EFA), the relationship between MLN concentration (x axis) and DNA crosslinks expressed as Ct (y axis) was best described by a power curve (y = 0.28 x 0.81; r = 0.985). The respective Ct values at the EC37 and EC10 of MLN were 1.3 and 3.8%. It appears that the sensitivity of the EFA is similar to the alkaline elution assay and, in addition, that the EFA is less technically difficult to employ with tumor cells obtained from patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401250     DOI: 10.1016/0006-2952(88)90319-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

Review 1.  Formation and repair of interstrand cross-links in DNA.

Authors:  David M Noll; Tracey McGregor Mason; Paul S Miller
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

Review 2.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  M J Moore
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

3.  Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.

Authors:  A L Vahrmeijer; J H van Dierendonck; H J Keizer; J H Beijnen; R A Tollenaar; M E Pijl; A Marinelli; P J Kuppen; J H van Bockel; G J Mulder; C J van de Velde
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.